NCT03289741

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

Conditions

• Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	Octreotide	Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
DRUG	LAR Lanreotide	Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
BEHAVIORAL	Questionnaires	Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.

Timeline

• Start date: 2017-09-19
• Primary completion: 2023-04-10
• Completion: 2023-04-10
• First posted: 2017-09-21
• Last updated: 2025-05-09
• Results posted: 2025-05-09

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study